Jamialahmadi Tannaz, Reiner Zeljko, Riahi Maryam Matbou, Emami Seyed Ahmad, Tayarani-Najaran Zahra, Salehabadi Sepideh, Kesharwani Prashant, Al-Rasadi Khalid, Sahebkar Amirhossein
International UNESCO center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran.
Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Curr Med Chem. 2025;32(7):1323-1332. doi: 10.2174/0929867331666230918114451.
Statins are primarily used to decrease elevated LDL-cholesterol and thus prevent atherosclerotic cardiovascular disease. Portal hypertension is one of the most important complications of chronic liver disease. Several studies indicated that statins might be beneficial for portal hypertension as well but there is still no clear answer whether this is true or not.
A literature search of the major databases was performed to find eligible randomized controlled trials (RCTs) analyzing the effect of statins on portal hypertension from inception to February 5th, 2021. Six RCTs with 442 patients who received statin or statin plus carvedilol were finally included. Meta-analysis was performed using the Comprehensive Meta-Analysis V2 software.
Reduction of portal hypertension after statin treatment was not significant (WMD: -0.494, 95% CI: -1.239, 0.252, p=0.194; I2:0%). The reduction of portal hypertension was robust in the leave-one-out sensitivity analysis.
Treatment with statins did not decrease significantly portal hypertension.
他汀类药物主要用于降低升高的低密度脂蛋白胆固醇，从而预防动脉粥样硬化性心血管疾病。门静脉高压是慢性肝病最重要的并发症之一。多项研究表明，他汀类药物可能对门静脉高压也有益，但这是否属实仍尚无明确答案。
对主要数据库进行文献检索，以查找从开始到2021年2月5日分析他汀类药物对门静脉高压影响的合格随机对照试验（RCT）。最终纳入了6项随机对照试验，共442例接受他汀类药物或他汀类药物加卡维地洛治疗的患者。使用综合荟萃分析V2软件进行荟萃分析。
他汀类药物治疗后门静脉高压的降低不显著（加权均数差：-0.494，95%置信区间：-1.239，0.252，p = 0.194；I²：0%）。在逐一剔除敏感性分析中，门静脉高压的降低是稳健的。
他汀类药物治疗并未显著降低门静脉高压。
